P Uusalo1,2, D Al-Ramahi3, I Tilli4, R A Aantaa5, M Scheinin3, T I Saari4,5. 1. Department of Anaesthesiology and Intensive Care, University of Turku, P.O. Box 51, (Kiinamyllynkatu 4-8), 20521, Turku, Finland. pijuus@utu.fi. 2. Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland. pijuus@utu.fi. 3. Institute of Biomedicine, University of Turku, and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland. 4. Department of Anaesthesiology and Intensive Care, University of Turku, P.O. Box 51, (Kiinamyllynkatu 4-8), 20521, Turku, Finland. 5. Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland.
Abstract
PURPOSE: Palliative care patients often need sedation to alleviate intractable anxiety, stress, and pain. Dexmedetomidine is used for sedation of intensive care patients, but there is no prior information on its subcutaneous (SC) administration, a route that would be favored in palliative care. We compared the pharmacokinetics and cardiovascular, sympatholytic, and sedative effects of SC and intravenously (IV) administered dexmedetomidine in healthy volunteers. METHODS: An open two-period, cross-over design with balanced randomization was used. Ten male subjects were randomized to receive 1 μg/kg dexmedetomidine both IV and SC. Concentrations of dexmedetomidine and catecholamines in plasma were measured. Pharmacokinetic variables were calculated with non-compartmental methods. In addition, cardiovascular and sedative drug effects were monitored. RESULTS: Eight subjects completed both treatment periods. Peak concentrations of dexmedetomidine were observed 15 min after SC administration (median; range 15-240). The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%). The mean (SD) peak concentration of dexmedetomidine in plasma was 0.3 (0.1) ng/ml, and plasma concentrations associated with sedative effects (i.e., > 0.2 ng/ml) were maintained for 4 h after SC dosing. Plasma noradrenaline concentrations were significantly lower (P < 0.001) within 3 h after IV than after SC administration. Subjective scores for vigilance and performance were significantly lower 0-60 min after IV than SC dosing (P < 0.001 for both). The onset of the cardiovascular, sympatholytic, and sedative effects of dexmedetomidine was clearly less abrupt after SC than IV administration. CONCLUSIONS:Dexmedetomidine is relatively rapidly and efficiently absorbed after SC administration. Subcutaneous dexmedetomidine may be a feasible alternative in palliative sedation, and causes attenuated cardiovascular effects compared to IV administration. CLINICALTRIALS. GOV IDENTIFIER: NCT02724098 . EUDRA CT number 2015-004698-34 .
RCT Entities:
PURPOSE: Palliative care patients often need sedation to alleviate intractable anxiety, stress, and pain. Dexmedetomidine is used for sedation of intensive care patients, but there is no prior information on its subcutaneous (SC) administration, a route that would be favored in palliative care. We compared the pharmacokinetics and cardiovascular, sympatholytic, and sedative effects of SC and intravenously (IV) administered dexmedetomidine in healthy volunteers. METHODS: An open two-period, cross-over design with balanced randomization was used. Ten male subjects were randomized to receive 1 μg/kg dexmedetomidine both IV and SC. Concentrations of dexmedetomidine and catecholamines in plasma were measured. Pharmacokinetic variables were calculated with non-compartmental methods. In addition, cardiovascular and sedative drug effects were monitored. RESULTS: Eight subjects completed both treatment periods. Peak concentrations of dexmedetomidine were observed 15 min after SC administration (median; range 15-240). The mean bioavailability of SC dexmedetomidine was 81% (AUC0-∞ ratio × 100%, range 49-97%). The mean (SD) peak concentration of dexmedetomidine in plasma was 0.3 (0.1) ng/ml, and plasma concentrations associated with sedative effects (i.e., > 0.2 ng/ml) were maintained for 4 h after SC dosing. Plasma noradrenaline concentrations were significantly lower (P < 0.001) within 3 h after IV than after SC administration. Subjective scores for vigilance and performance were significantly lower 0-60 min after IV than SC dosing (P < 0.001 for both). The onset of the cardiovascular, sympatholytic, and sedative effects of dexmedetomidine was clearly less abrupt after SC than IV administration. CONCLUSIONS:Dexmedetomidine is relatively rapidly and efficiently absorbed after SC administration. Subcutaneous dexmedetomidine may be a feasible alternative in palliative sedation, and causes attenuated cardiovascular effects compared to IV administration. CLINICALTRIALS. GOV IDENTIFIER: NCT02724098 . EUDRA CT number 2015-004698-34 .
Authors: Pratik Pandharipande; Ayumi Shintani; Josh Peterson; Brenda Truman Pun; Grant R Wilkinson; Robert S Dittus; Gordon R Bernard; E Wesley Ely Journal: Anesthesiology Date: 2006-01 Impact factor: 7.892
Authors: Maria Wujtewicz; Dariusz Maciejewski; Hanna Misiołek; Anna Fijałkowska; Tomasz Gaszyński; Piotr Knapik; Romuald Lango Journal: Anaesthesiol Intensive Ther Date: 2013 Oct-Dec
Authors: Åse Lodenius; Anette Ebberyd; Anna Hårdemark Cedborg; Eva Hagel; Souren Mkrtchian; Eva Christensson; Johan Ullman; Mika Scheinin; Lars I Eriksson; Malin Jonsson Fagerlund Journal: Anesthesiology Date: 2016-10 Impact factor: 7.892
Authors: H Scheinin; S Karhuvaara; K T Olkkola; A Kallio; M Anttila; L Vuorilehto; M Scheinin Journal: Clin Pharmacol Ther Date: 1992-11 Impact factor: 6.875
Authors: Vanessa Rabbogliatti; Martina Amari; Federica Alessandra Brioschi; Federica Di Cesare; Davide Danilo Zani; Donatella De Zani; Mauro Di Giancamillo; Petra Cagnardi; Giuliano Ravasio Journal: BMC Vet Res Date: 2022-07-11 Impact factor: 2.792